Cargando…

Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma—A Real World Single-Center Analysis

SIMPLE SUMMARY: Adjuvant treatment with the immune checkpoint inhibitors (ICI) pembrolizumab or nivolumab, or the targeted therapies dabrafenib and trametinib is recommended for patients with completely resected stage III melanoma and significantly decreases recurrence risk. Currently, limited data...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoffmann, Michèle, Hayoz, Stefanie, Özdemir, Berna C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945449/ https://www.ncbi.nlm.nih.gov/pubmed/35336796 http://dx.doi.org/10.3390/biology11030422

Ejemplares similares

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
por: Mandalá, Mario, et al.
Publicado: (2021)

Clinical predictors of survival in real world practice in stage IV melanoma
por: Hu, Hsien‐Pang, et al.
Publicado: (2022)

Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy
por: Bhave, Prachi, et al.
Publicado: (2023)

The cost of unresectable stage III or stage IV melanoma in Italy
por: Maio, Michele, et al.
Publicado: (2012)

A real‐world study of adjuvant anti‐PD ‐1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations
por: Sun, Wei, et al.
Publicado: (2023)

Adjuvant Anti-PD-1 Immunotherapy versus Conventional Therapy for Stage III Melanoma: A Real-World Retrospective Cohort Study
por: Li, Tong, et al.
Publicado: (2022)

The role of immune checkpoint inhibitors in clinical practice: an analysis of the treatment patterns, survival and toxicity rates by sex
por: Wahli, Murielle N., et al.
Publicado: (2022)

Comparative analysis of adjuvant therapy for stage III BRAF‐mut melanoma: A real‐world retrospective study from single center in China
por: Zhong, Jingqin, et al.
Publicado: (2023)

New paradigm for stage III melanoma: from surgery to adjuvant treatment
por: Ascierto, Paolo Antonio, et al.
Publicado: (2019)

Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer
por: Batra, Atul, et al.
Publicado: (2020)

Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV)
por: Lotem, M, et al.
Publicado: (2002)

Correction to: New paradigm for stage III melanoma: from surgery to adjuvant treatment
por: Ascierto, Paolo Antonio, et al.
Publicado: (2019)

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
por: Larkin, James, et al.
Publicado: (2023)

Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma
por: Jang, Sekwon, et al.
Publicado: (2020)

Results of systemic treatment of cutaneous melanoma in inoperable stage III and IV
por: Cybulska-Stopa, Bożena, et al.
Publicado: (2013)

Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR
por: Giunta, Emilio Francesco, et al.
Publicado: (2022)

Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma
por: Sun, Meiling, et al.
Publicado: (2022)

Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews
por: Livingstone, Ann, et al.
Publicado: (2021)

Factors associated with the use of adjuvant radiation therapy in stage III melanoma
por: King, Amber L. O., et al.
Publicado: (2023)

Correction to: Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma
por: Jang, Sekwon, et al.
Publicado: (2020)

Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial)
por: Kähler, Katharina C., et al.
Publicado: (2023)

Real‐world outcomes of advanced melanoma patients not represented in phase III trials
por: van Zeijl, Michiel C. T., et al.
Publicado: (2020)

Real-world outcomes and toxicity of adjuvant chemotherapy in NSCLC: a single-center experience
por: Cronin, Christopher, et al.
Publicado: (2023)

Prediction of Biochemical Recurrence Based on Molecular Detection of Lymph Node Metastasis After Radical Prostatectomy
por: Özdemir, Berna C., et al.
Publicado: (2022)

The meaning of screening: detection of brain metastasis in the adjuvant setting for stage III melanoma
por: Derks, S.H.A.E., et al.
Publicado: (2022)

Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
por: Samlowski, Wolfram, et al.
Publicado: (2022)

Survival benefit of adjuvant radiotherapy in stage III and IV bladder cancer: results of 170 patients
por: Bayoumi, Yasser, et al.
Publicado: (2014)

Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment
por: Chou, Wen-Chi, et al.
Publicado: (2013)

Spectroscopic and Imaging Characteristics of Pigmented Non-Melanoma Skin Cancer and Melanoma in Patients with Skin Phototypes III and IV
por: Arroyo-Camarena, Stefanie, et al.
Publicado: (2016)

Clinical trials with MRNA electroporated dendritic cells for stage III/IV melanoma patients
por: Wilgenhof, Sofie, et al.
Publicado: (2015)

Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients
por: Aoude, Lauren G., et al.
Publicado: (2020)

A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis
por: Vreeland, Timothy J., et al.
Publicado: (2021)

Comparison of efficacy and tolerability of adjuvant therapy for resected high-risk stage III-IV cutaneous melanoma: a systemic review and Bayesian network meta-analysis
por: Ba, He, et al.
Publicado: (2023)

Real-World Effectiveness of Adjuvant Oxaliplatin Chemotherapy in Stage III Colon Cancer: A Controlled Interrupted Time Series Analysis
por: Huang, Wen-Kuan, et al.
Publicado: (2021)

Definitive Chemoradiotherapy Versus Surgery Followed by Adjuvant Radiotherapy in Resectable Stage III/IV Hypopharyngeal Cancer
por: Kim, Jun Won, et al.
Publicado: (2016)

A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence
por: Weber, Jeffrey, et al.
Publicado: (2015)

Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade
por: Johannet, Paul, et al.
Publicado: (2022)

Correction: Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment
por: Chou, Wen-Chi, et al.
Publicado: (2013)

Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III/IV melanoma
por: Oldan, Jorge D., et al.
Publicado: (2023)

Maspin is a marker for early recurrence in primary stage III and IV colorectal cancer
por: Snoeren, N, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4m80kb297klhkkr8l9i0ccbau5